drug_type
RELEVANT_DRUG
intervention_type
Antibody-drug conjugate
drug_description
An anti-HER2 antibody–drug conjugate (humanized IgG1) given IV every 2 weeks. It binds HER2 (ERBB2) on tumor cells, is internalized, and a cleavable linker releases the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor that induces G2/M arrest and apoptosis; the IgG1 Fc can trigger ADCC and released MMAE may produce a bystander effect.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-HER2 (ERBB2) IgG1 antibody–drug conjugate that binds HER2 on tumor cells, is internalized, and via a cleavable linker releases the cytotoxic payload MMAE, a microtubule inhibitor causing G2/M arrest and apoptosis; the IgG1 Fc can mediate ADCC, and released MMAE may produce a bystander effect.
drug_name
Disitamab vedotin (RC48-ADC)
nct_id_drug_ref
NCT05955209